Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.

McKesey J, Pandya AG.

J Am Acad Dermatol. 2019 Aug;81(2):646-648. doi: 10.1016/j.jaad.2019.04.032. Epub 2019 Apr 19. No abstract available.

PMID:
31009664
2.

Validation of a physician global assessment tool for vitiligo extent: Results of an international vitiligo expert meeting.

van Geel N, Wolkerstorfer A, Ezzedine K, Pandya AG, Bekkenk M, Grine L, Van Belle S, Lommerts JE, Hamzavi I, Harris JE, Eleftheriadou V, Esmat S, Kang HY, Kumarasinghe P, Lan CE, Parsad D, Raboobee N, Flora Xiang L, Suzuki T, Prinsen CA, Taieb A, Picardo M, Speeckaert R; participants of the Rome International VGICC /VIS Workshop.

Pigment Cell Melanoma Res. 2019 Apr 3. doi: 10.1111/pcmr.12784. [Epub ahead of print]

PMID:
30945409
3.

Disorders of Hypopigmentation

Dina Y, McKesey J, Pandya AG.

J Drugs Dermatol. 2019 Mar 1;18(3):s115-s116.

PMID:
30909355
4.

Noncultured epidermal suspension grafting using suction blisters as donor tissue for vitiligo.

Tovar-Garza A, Hinojosa JA, Hynan LS, Pandya AG.

J Am Acad Dermatol. 2019 Apr;80(4):1152-1154. doi: 10.1016/j.jaad.2018.10.041. Epub 2018 Oct 27. No abstract available.

PMID:
30393095
5.

Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo.

Tovar-Garza A, Hinojosa JA, Hynan LS, Pandya AG.

Br J Dermatol. 2019 Jan;180(1):193-194. doi: 10.1111/bjd.17150. Epub 2018 Oct 10. No abstract available.

PMID:
30188576
6.

International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation.

Eleftheriadou V, Hamzavi I, Pandya AG, Grimes P, Harris JE, Huggins RH, Lim HW, Elbuluk N, Bhatia B, Tovar-Garza A, Nahhas AF, Braunberger T, Ezzedine K.

Br J Dermatol. 2019 Mar;180(3):574-579. doi: 10.1111/bjd.17013. Epub 2018 Oct 5.

PMID:
30030843
7.

Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo.

Richmond JM, Strassner JP, Zapata L Jr, Garg M, Riding RL, Refat MA, Fan X, Azzolino V, Tovar-Garza A, Tsurushita N, Pandya AG, Tso JY, Harris JE.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaam7710. doi: 10.1126/scitranslmed.aam7710.

PMID:
30021889
8.

The effect of melasma on self-esteem: A pilot study.

Jiang J, Akinseye O, Tovar-Garza A, Pandya AG.

Int J Womens Dermatol. 2017 Dec 8;4(1):38-42. doi: 10.1016/j.ijwd.2017.11.003. eCollection 2018 Mar.

9.

Successful treatment with narrowband ultraviolet B phototherapy of burn-induced leucoderma.

Hinojosa JA, Tovar-Garza A, Pandya AG.

Br J Dermatol. 2018 May;178(5):e327. doi: 10.1111/bjd.16419. No abstract available.

PMID:
29785828
10.

Oral Tranexamic Acid for the Treatment of Melasma: A Review.

Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M.

Dermatol Surg. 2018 Jun;44(6):814-825. doi: 10.1097/DSS.0000000000001518. Review.

PMID:
29677015
11.

Diversity in dermatology: Roadmap for improvement.

Pritchett EN, Pandya AG, Ferguson NN, Hu S, Ortega-Loayza AG, Lim HW.

J Am Acad Dermatol. 2018 Aug;79(2):337-341. doi: 10.1016/j.jaad.2018.04.003. Epub 2018 Apr 10.

PMID:
29653209
12.

Lack of correlation of the patient-derived Vitiligo Disease Activity Index with the clinician-derived Vitiligo Area Scoring Index.

Coias J, Hynan LS, Pandya AG.

J Am Acad Dermatol. 2018 May;78(5):1015-1016. doi: 10.1016/j.jaad.2017.11.034. Epub 2017 Nov 24. No abstract available.

PMID:
29180097
13.

Lichen planus pigmentosus and its variants: review and update.

Robles-Méndez JC, Rizo-Frías P, Herz-Ruelas ME, Pandya AG, Ocampo Candiani J.

Int J Dermatol. 2018 May;57(5):505-514. doi: 10.1111/ijd.13806. Epub 2017 Oct 26. Review.

PMID:
29076159
14.

Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma.

Del Rosario E, Florez-Pollack S, Zapata L Jr, Hernandez K, Tovar-Garza A, Rodrigues M, Hynan LS, Pandya AG.

J Am Acad Dermatol. 2018 Feb;78(2):363-369. doi: 10.1016/j.jaad.2017.09.053. Epub 2017 Oct 4.

PMID:
28987494
15.

Cultural competence for the 21st century dermatologist practicing in the United States.

McKesey J, Berger TG, Lim HW, McMichael AJ, Torres A, Pandya AG.

J Am Acad Dermatol. 2017 Dec;77(6):1159-1169. doi: 10.1016/j.jaad.2017.07.057. Epub 2017 Sep 28. Review.

PMID:
28964536
16.

The Importance of Patient Registries in Skin of Color.

Hinojosa JA, Pandya AG.

J Investig Dermatol Symp Proc. 2017 Oct;18(2):S31-S33. doi: 10.1016/j.jisp.2017.01.002. Review.

17.

The majority of patients presenting with vitiligo have a clinical sign of activity.

Aboul-Fettouh N, Hinojosa J, Tovar-Garza A, Pandya AG.

J Am Acad Dermatol. 2017 Oct;77(4):774-775. doi: 10.1016/j.jaad.2017.05.027. No abstract available.

PMID:
28917464
18.

Quality of life in patients with vitiligo using the Short Form-36.

Yang Y, Zapata L, Rodgers C, Hernandez K, Iyer M, Jia G, Hynan LS, Pandya AG.

Br J Dermatol. 2017 Dec;177(6):1764-1766. doi: 10.1111/bjd.15936. Epub 2017 Nov 15. No abstract available.

PMID:
28872663
19.

A cross-sectional, comparative study of home vs in-office NB-UVB phototherapy for vitiligo.

Dillon JP, Ford C, Hynan LS, Pandya AG.

Photodermatol Photoimmunol Photomed. 2017 Sep;33(5):282-283. doi: 10.1111/phpp.12326. Epub 2017 Jul 14. No abstract available.

PMID:
28660721
20.

Current and emerging treatments for vitiligo.

Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE; Vitiligo Working Group.

J Am Acad Dermatol. 2017 Jul;77(1):17-29. doi: 10.1016/j.jaad.2016.11.010. Review.

PMID:
28619557
21.

New discoveries in the pathogenesis and classification of vitiligo.

Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE; Vitiligo Working Group.

J Am Acad Dermatol. 2017 Jul;77(1):1-13. doi: 10.1016/j.jaad.2016.10.048. Review.

PMID:
28619550
22.

Presentations, Signs of Activity, and Differential Diagnosis of Vitiligo.

Goh BK, Pandya AG.

Dermatol Clin. 2017 Apr;35(2):135-144. doi: 10.1016/j.det.2016.11.004. Review.

PMID:
28317523
23.

The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo.

Mohammad TF, Al-Jamal M, Hamzavi IH, Harris JE, Leone G, Cabrera R, Lim HW, Pandya AG, Esmat SM.

J Am Acad Dermatol. 2017 May;76(5):879-888. doi: 10.1016/j.jaad.2016.12.041. Epub 2017 Feb 16.

PMID:
28216034
24.

A Missed Opportunity to Discuss Racial and Gender Bias in Dermatology.

Adamson AS, Wright SW, Pandya AG.

JAMA Dermatol. 2017 Jan 1;153(1):110-111. doi: 10.1001/jamadermatol.2016.3752. No abstract available.

PMID:
28114518
25.

Association of Quality of Life and Location of Lesions in Patients With Vitiligo.

Florez-Pollack S, Jia G, Zapata L Jr, Rodgers C, Hernandez K, Hynan LS, Pandya AG.

JAMA Dermatol. 2017 Mar 1;153(3):341-342. doi: 10.1001/jamadermatol.2016.4670. No abstract available.

PMID:
28097309
26.

Diversity in the dermatology workforce.

Hinojosa JA, Pandya AG.

Semin Cutan Med Surg. 2016 Dec;36(4):242-245. doi: 10.12788/j.sder.2016.063.

PMID:
27918008
27.

Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference.

Gan EY, Eleftheriadou V, Esmat S, Hamzavi I, Passeron T, Böhm M, Anbar T, Goh BK, Lan CE, Lui H, Ramam M, Raboobee N, Katayama I, Suzuki T, Parsad D, Seth V, Lim HW, van Geel N, Mulekar S, Harris J, Wittal R, Benzekri L, Gauthier Y, Kumarasinghe P, Thng ST, Silva de Castro CC, Abdallah M, Vrijman C, Bekkenk M, Seneschal J, Pandya AG, Ezzedine K, Picardo M, Taïeb A; VGICC.

Pigment Cell Melanoma Res. 2017 Jan;30(1):28-40. doi: 10.1111/pcmr.12561.

PMID:
27864868
28.

Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease.

Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG, Youd ME, Luster AD, Harris JE.

J Invest Dermatol. 2017 Feb;137(2):350-358. doi: 10.1016/j.jid.2016.09.016. Epub 2016 Sep 26.

29.

Acne Knowledge of Hispanic Parents of Teenagers with Mild to Moderate Acne.

Lopez I, Zapata L Jr, Sosa JJ, Rodgers C, Ruiz M, Oh S, Hynan LS, Kimball AB, Pandya AG.

Pediatr Dermatol. 2016 Sep;33(5):e292-3. doi: 10.1111/pde.12934. Epub 2016 Jul 11.

PMID:
27397689
30.

Interpretability of the Modified Melasma Area and Severity Index (mMASI).

Rodrigues M, Ayala-Cortés AS, Rodríguez-Arámbula A, Hynan LS, Pandya AG.

JAMA Dermatol. 2016 Sep 1;152(9):1051-2. doi: 10.1001/jamadermatol.2016.1006. No abstract available.

PMID:
27144383
31.

Use of Suction Blisters for Noncultured Epidermal Suspension Grafting in Patients With Vitiligo.

Jeong HS, Vandergriff T, Pandya AG.

Dermatol Surg. 2016 May;42(5):688-91. doi: 10.1097/DSS.0000000000000709. No abstract available.

PMID:
27093580
32.

Increasing racial and ethnic diversity in dermatology: A call to action.

Pandya AG, Alexis AF, Berger TG, Wintroub BU.

J Am Acad Dermatol. 2016 Mar;74(3):584-7. doi: 10.1016/j.jaad.2015.10.044. Epub 2016 Jan 8. No abstract available.

PMID:
26774427
33.

Development and validation of a Hindi language health-related quality of life questionnaire for melasma in Indian patients.

Sarkar R, Garg S, Dominguez A, Balkrishnan R, Jain RK, Pandya AG.

Indian J Dermatol Venereol Leprol. 2016 Jan-Feb;82(1):16-22. doi: 10.4103/0378-6323.168937.

34.

Vitiligo is not a cosmetic disease.

Ezzedine K, Sheth V, Rodrigues M, Eleftheriadou V, Harris JE, Hamzavi IH, Pandya AG; Vitiligo Working Group.

J Am Acad Dermatol. 2015 Nov;73(5):883-5. doi: 10.1016/j.jaad.2015.07.039. No abstract available.

PMID:
26475548
35.

Response to 'Assessment of vitiligo severity: patient-reported estimates are not accurate': Reply from authors.

Ukoha UT, Sosa JJ, Hynan LS, Pandya AG.

Br J Dermatol. 2015 Nov;173(5):1340-1. doi: 10.1111/bjd.14209. Epub 2015 Oct 23. No abstract available.

PMID:
26408833
36.

A pilot study to determine vitiligo target size using a computer-based image analysis program.

Sheth VM, Rithe R, Pandya AG, Chandrakasan A.

J Am Acad Dermatol. 2015 Aug;73(2):342-5. doi: 10.1016/j.jaad.2015.04.035. No abstract available.

PMID:
26183989
37.

Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo.

Sosa JJ, Currimbhoy SD, Ukoha U, Sirignano S, O'Leary R, Vandergriff T, Hynan LS, Pandya AG.

J Am Acad Dermatol. 2015 Aug;73(2):272-5. doi: 10.1016/j.jaad.2015.05.014. Epub 2015 Jun 6.

PMID:
26054430
38.

Suction blister grafting for vitiligo: efficacy and clinical predictive factors.

Gou D, Currimbhoy S, Pandya AG.

Dermatol Surg. 2015 May;41(5):633-9. doi: 10.1097/DSS.0000000000000341.

PMID:
25899886
39.

Assessment of vitiligo severity: patient-reported estimates are not accurate.

Ukoha UT, Sosa JJ, Hynan LS, Pandya AG.

Br J Dermatol. 2015 Nov;173(5):1325-6. doi: 10.1111/bjd.13825. Epub 2015 Oct 19. No abstract available.

PMID:
25833124
40.

Rituximab in the treatment of 38 patients with Pemphigus with long-term follow-up.

Currimbhoy S, Zhu V, Dominguez AR, Pandya AG.

J Eur Acad Dermatol Venereol. 2016 Jun;30(6):1050-2. doi: 10.1111/jdv.13103. Epub 2015 Mar 19. No abstract available.

PMID:
25787106
41.

Patient satisfaction with different treatment modalities for vitiligo.

Adotama P, Zapata L Jr, Currimbhoy S, Hynan LS, Pandya AG.

J Am Acad Dermatol. 2015 Apr;72(4):732-3. doi: 10.1016/j.jaad.2014.12.012. No abstract available.

PMID:
25773415
42.

Melasma: clinical diagnosis and management options.

Rodrigues M, Pandya AG.

Australas J Dermatol. 2015 Aug;56(3):151-63. doi: 10.1111/ajd.12290. Epub 2015 Mar 9. Review.

PMID:
25754098
43.

Defining early mycosis fungoides: validation of a diagnostic algorithm proposed by the International Society for Cutaneous Lymphomas.

Vandergriff T, Nezafati KA, Susa J, Karai L, Sanguinetti A, Hynan LS, Ambruzs JM, Oliver DH, Pandya AG.

J Cutan Pathol. 2015 May;42(5):318-28. doi: 10.1111/cup.12470. Epub 2015 Apr 8.

PMID:
25721994
44.

Not too dark, not too light, the quest for skin, that's just right.

Pandya AG.

Indian J Dermatol Venereol Leprol. 2014 Sep-Oct;80(5):387-8. doi: 10.4103/0378-6323.140283. No abstract available.

45.

Serving the underserved: creating a low-cost sunscreen with natural ingredients for humanitarian medical trips to the developing world.

Miyar ME, Diven DG, Cosulich MT, Kidd LL, Braswell MA, Triplett TM, Pandya AG.

Br J Dermatol. 2014 Aug;171(2):415-7. doi: 10.1111/bjd.12993. Epub 2014 Aug 6. No abstract available.

PMID:
25040599
46.

What's new in objective assessment and treatment of facial hyperpigmentation?

Molinar VE, Taylor SC, Pandya AG.

Dermatol Clin. 2014 Apr;32(2):123-35. doi: 10.1016/j.det.2013.12.008. Review.

PMID:
24679999
47.

Beware of underlying malignancy: acquired ichthyosis.

Word AP, Cayce R, Pandya AG.

Am J Med. 2014 Mar;127(3):202-4. doi: 10.1016/j.amjmed.2013.12.009. Epub 2013 Dec 17. No abstract available.

PMID:
24355352
48.

Reliability assessment and validation of the postacne hyperpigmentation index (PAHPI), a new instrument to measure postinflammatory hyperpigmentation from acne vulgaris.

Savory SA, Agim NG, Mao R, Peter S, Wang C, Maldonado G, Bearden Dietert J, Lieu TJ, Wang C, Pretzlaff K, Das S, Vandergriff T, Lopez IE, Litzner BR, Hynan LS, Arellano-Mendoza MI, Bergstresser PR, Pandya AG.

J Am Acad Dermatol. 2014 Jan;70(1):108-14. doi: 10.1016/j.jaad.2013.09.017. Epub 2013 Oct 28.

PMID:
24176524
49.

Treatment of melasma with topical agents, peels and lasers: an evidence-based review.

Rivas S, Pandya AG.

Am J Clin Dermatol. 2013 Oct;14(5):359-76. doi: 10.1007/s40257-013-0038-4. Review.

PMID:
23881551
50.

A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma.

Ahmed AM, Lopez I, Perese F, Vasquez R, Hynan LS, Chong B, Pandya AG.

JAMA Dermatol. 2013 Aug;149(8):981-3. doi: 10.1001/jamadermatol.2013.4294. No abstract available.

PMID:
23740292

Supplemental Content

Loading ...
Support Center